RxDoctor Payments Data

Norma Henriquez, MD

Psychiatry · Naples, FLNPI 1053340976

Payments from drug & device makers

$4,062in general payments, 2019–2025

Across 103 payments — averaging $39.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Neuronetics, Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$678
  • Otsuka America Pharmaceutical, Inc.$241
  • Alkermes, Inc.$165
  • Takeda Pharmaceuticals U.S.A., Inc.$97
  • plus $451 from 11 others

What the payments were for

  • Travel & lodging$71318%
  • Food & beverage$3,27581%
  • Education$742%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,062 in reported general payments places this provider in the 75th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$64,731
Medicare patients
61
Services billed
630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl18$25,814
TrintellixVortioxetine Hydrobromide35$17,854
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl73$11,184
ZubsolvBuprenorphine Hcl/Naloxone Hcl15$7,572
Quetiapine Fumarate257$3,340
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine92$3,166
Buprenorphine Hcl101$2,418
Desvenlafaxine Succinate ErDesvenlafaxine Succinate88$2,200
Mirtazapine136$2,143
Oxcarbazepine82$1,605
Aripiprazole84$1,553
Divalproex Sodium ErDivalproex Sodium40$1,445
Buspirone Hcl121$1,183
Clonazepam179$1,149
Bupropion XlBupropion Hcl86$1,040

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,268$25,81418 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$97$17,85435 claims
Orexo US, Inc.Zubsolv$24$7,57215 claims
Almatica Pharma LLCSertraline Hcl$75$427107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →